Coming back to post #5, because the follow-up matters more than the original answer. Adding a null result on consumer-accessible tests. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
What consumer-accessible tests can and cannot determine — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below.
Posting a small dataset on consumer-accessible tests. It is mine, it is uncontrolled, and the method is stated so it can be discounted appropriately.
What I would like is not agreement but a second dataset collected by someone with no stake in mine. If one exists I would rather read it than argue for this one.
The opening post is right about the mechanism and I think understates the practical bit.
Trying to state the consumer-accessible tests position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
What physical quantity does the device measure? A colorimetric or lateral-flow method typically responds to a class of chemistry rather than to a specific molecule. It can distinguish "peptide present" from "nothing present" but generally cannot distinguish the intended peptide from a closely related one.
That is the practical version. The rigorous version is longer and says the same thing.
Immunoassay limitations: tests that use antibodies have cross-reactivity limitations. An antibody raised to semaglutide will cross-react to some degree with tirzepatide and other structurally similar compounds. The test result conflates them.
For what it is worth, the same held on the two occasions I checked.
This is the sort of exchange that makes the archive worth searching.
Consumer-accessible tests would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
Clear enough that I do not think I have a follow-up, which is unusual.
Molecular tests: DNA or RNA tests are not applicable to peptides, which do not contain nucleic acids. Peptide-specific tests rely on protein recognition, not nucleic-acid detection.
I would call that likely rather than established.
Ultraviolet absorbance at 280 nanometres estimates concentration for peptides containing aromatic residues and gives nothing for peptides that do not. Knowing which yours is comes first.
On post #8 — agreed on the reasoning, with one qualification.
Two questions I would want answered before drawing anything from the consumer-accessible tests data above: how were the cases selected, and what happened to the ones that dropped out.
On consumer-accessible tests the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.
Precision of home tests: most consumer-accessible devices are not precise to the level people want ("is this 99% pure or 97% pure"). They give a yes/no or a rough category, not a quantitative number.
The honest answer is that it depends, and here is what it depends on.
Post #14 is right about the mechanism and I think understates the practical bit.
I would keep consumer-accessible tests and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.
Worth separating two things that post #13 runs together.
Colorimetric tests: colour intensity correlates with concentration, but the relationship is non-linear at extremes and the correlation depends on the exact conditions (pH, temperature, timing). Reading the colour visually introduces subjectivity.
That holds under the stated conditions and I have stated them.
The right question for any home test is: what physical quantity does it measure, and what would have to be true for that quantity to answer your question? Most disappointment comes from skipping it.
Post #18 answers the question as asked. The question underneath it is different.
A test that gives a yes or no on the presence of peptide bonds is answering a genuinely useful question if that is the question you had. It is not a purity assay and cannot be read as one.
That is one dataset and I would not build a rule on it.
The honest cost comparison is a home kit against a single independent submission. For most people the second answers the question and the first answers a different, smaller one.
Worth reading the earlier posts in this thread before acting on mine.
What you can use home tests for: confirmation that a solution contains peptide (as opposed to being saline alone), rough screening for very different compounds (semaglutide versus totally unrelated compound). What you cannot use them for: precise purity assessment or verification that the identity is correct.
Not the whole picture, but the part of it I can speak to.
Enzyme assays: if you have an enzyme that reacts specifically with your compound, an enzyme-based assay can work. These are sometimes available commercially but are less common than antibody-based tests.
None of the above is medical advice and I am not qualified to give any.
I read post #21 twice before replying, because I had assumed the opposite.
Taking consumer-accessible tests seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.
Marking my uncertainty on consumer-accessible tests explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.
What you can use home tests for: confirmation that a solution contains peptide (as opposed to being saline alone), rough screening for very different compounds (semaglutide versus totally unrelated compound). What you cannot use them for: precise purity assessment or verification that the identity is correct.
Not a strong opinion, just a consistent one.